FCGR2A and breast carcinoma: Guided by assessing the presence of FcγR-expressing immune effector cells in the breast cancer TME, including NAC- and immunotherapy-resistant disease, we designed and evaluated Fc-engineered antibodies with enhanced affinity for the prominently expressed FcγRIIIa.